Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Nurix Therapeutics reported a sharp earnings miss (-10.96%) and a much larger revenue decline/miss (-36.76%) for the quarter ended May 2026. The magnitude of the revenue shortfall raises concerns about near-term fundamentals and likely keeps the stock biased to downside until visibility improves. Investors will focus on what management and guidance (if any) signal about demand and cost structure going forward.

Analysis

Nurix Therapeutics reported a sharp earnings miss (-10.96%) and a much larger revenue decline/miss (-36.76%) for the quarter ended May 2026. The magnitude of the revenue shortfall raises concerns about near-term fundamentals and likely keeps the stock biased to downside until visibility improves. Investors will focus on what management and guidance (if any) signal about demand and cost structure going forward.